|
1
|
Ukawa M, Fujiwara Y, Ando H, Shimizu T and
Ishida T: Hepatic tumor metastases cause enhanced PEGylated
liposome uptake by Kupffer cells. Biol Pharm Bull. 39:215–220.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Balermpas P, Stera S, von der Grün Müller
J, Loutfi-Krauss B, Forster MT, Wagner M, Keller C, Rödel C,
Seifert V, Blanck O and Wolff R: Repeated in-field radiosurgery for
locally recurrent brain metastases: Feasibility, results and
survival in a heavily treated patient cohort. PLoS One.
13:e01986922018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kotecha R, Suh JH, Barnett GH, Murphy ES,
Ahluwalia M, Reddy CA, Vogelbaum MA, Angelov L, Mohammadi AM,
Stevens GHJ, et al: Changing trends in brain metastasis: A 20-year
review of patient outcomes. Int J Radiat Oncol Biol Phys.
96:E5182016. View Article : Google Scholar
|
|
4
|
Zheng R, Yao Q, Xie G, Du S, Ren C, Wang Y
and Yuan Y: TAT-ODD-p53 enhances the radiosensitivity of hypoxic
breast cancer cells by inhibiting Parkin-mediated mitophagy.
Oncotarget. 6:17417–17429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stępień K, Ostrowski RP and Matyja E:
Hyperbaric oxygen as an adjunctive therapy in treatment of
malignancies, including brain tumours. Med Oncol. 33:1012016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leber KA, Eder HG, Kovac H, Anegg U and
Pendl G: Treatment of cerebral radionecrosis by hyperbaric oxygen
therapy. Stereotact Funct Neurosurg. 70:229–236. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohguri T, Imada H, Kohshi K, Kakeda S,
Ohnari N, Morioka T, Nakano K, Konda N and Korogi Y: Effect of
prophylactic hyperbaric oxygen treatment for radiation-induced
brain injury after stereotactic radiosurgery of brain metastases.
Int J Radiat Oncol Biol Phys. 67:248–255. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cosse JP and Michiels C: Tumour hypoxia
affects the responsiveness of cancer cells to chemotherapy and
promotes cancer progression. Anticancer Agents Med Chem. 8:790–797.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mendes O, Kim HT and Stoica G: Expression
of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat
model. Clin Exp Metastasis. 22:237–246. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Castellano G, Malaponte G, Mazzarino MC,
Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S
and Libra M: Activation of the osteopontin/matrix
metalloproteinase-9 pathway correlates with prostate cancer
progression. Clin Cancer Res. 14:7470–7480. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takafuji V, Forgues M, Unsworth E,
Goldsmith P and Wang XW: An osteopontin fragment is essential for
tumor cell invasion in hepatocellular carcinoma. Oncogene.
26:6361–6371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song G, Ouyang G, Mao Y, Ming Y, Bao S and
Hu T: Osteopontin promotes gastric cancer metastasis by augmenting
cell survival and invasion through Akt-mediated HIF-1alpha
up-regulation and MMP9 activation. J Cell Mol Med. 13:1706–1718.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rangaswami H and Kundu GC: Osteopontin
stimulates melanoma growth and lung metastasis through
NIK/MEKK1-dependent MMP-9 activation pathways. Oncol Rep.
18:909–915. 2007.PubMed/NCBI
|
|
15
|
Kerenidi T, Kazakou AP, Lada M, Tsilioni
I, Daniil Z and Gourgoulianis KI: Clinical significance of
circulating osteopontin levels in patients with lung cancer and
correlation with VEGF and MMP-9. Cancer Invest. 34:385–392. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei R, Wong JPC and Kwok HF: Osteopontin-a
promising biomarker for cancer therapy. J Cancer. 8:2173–2183.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Dammer EB, Zhang-Brotzge X, Chen S,
Duong DM, Seyfried NT, Kuan CY and Sun YY: Osteopontin is a blood
biomarker for microglial activation and brain injury in
experimental hypoxic-ischemic encephalopathy. eNeuro.
4:ENEURO.0253-16.2016. 2017. View Article : Google Scholar
|
|
18
|
Bednarek N, Svedin P, Garnotel R, Favrais
G, Loron G, Schwendiman L, Hagberg H, Morville P, Mallard C and
Gressens P: Increased MMP-9 and TIMP-1 in mouse neonatal brain and
plasma and in human neonatal plasma after hypoxia-ischemia: A
potential marker of neonatal encephalopathy. Pediatr Res. 71:63–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin J, Huang SM, Zhu J, Chen SM, Chen WX,
Wu GG and Zhao TX: Kangai injection and palliative treatment of
hepatocellular carcinoma and survival analysis in patients with
advanced hepatocellular carcinoma. Zhongjua Zhong Yi Yuan Xue Kan.
36:1278–1280. 2018.(In Chinese).
|
|
20
|
Chen CX, Wang YW, Yu HY, Wu XH and Fan XL:
Effects of palliative treatment on short-term quality of life
improvement in patients with advanced malignant tumors. Huli
Shijian Yu Yanjiu. 15:98–100. 2018.(In Chinese).
|
|
21
|
van der Bel R, Sliggers BC, van
Houwelingen MJ, van Lieshout JJ, Halliwill JR, van Hulst RA and
Krediet CT: A modified device for continuous non-invasive blood
pressure measurements in humans under hyperbaric and/or
oxygen-enriched conditions. Diving Hyperb Med. 46:38–42.
2016.PubMed/NCBI
|
|
22
|
Mazanec P and Prince-Paul M: Integrating
palliative care into active cancer treatment. Semin Oncol Nurs.
30:203–211. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chan DL, Pavlakis N, Schembri GP, Bernard
EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, et
al: Dual somatostatin receptor/FDG PET/CT imaging in metastatic
neuroendocrine tumours: Proposal for a novel grading scheme with
prognostic significance. Theranostics. 7:1149–1158. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shinagare AB, Barysauskas CM,
Braschi-Amirfarzan M, O'Neill AC, Catalano PJ, George S and Ramaiya
NH: Comparison of performance of various tumor response criteria in
assessment of sunitinib activity in advanced gastrointestinal
stromal tumors. Clin Imaging. 40:880–884. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi H, Charnsangavej C, Faria SC,
Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and
Benjamin RS: Correlation of computed tomography and positron
emission tomography in patients with metastatic gastrointestinal
stromal tumor treated at a single institution with imatinib
mesylate: Proposal of new computed tomography response criteria. J
Clin Oncol. 25:1753–1759. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stacchiotti S, Verderio P, Messina A,
Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz
J, Ferraro A, et al: Tumor response assessment by modified Choi
criteria in localized high-risk soft tissue sarcoma treated with
chemotherapy. Cancer. 118:5857–5866. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Greimel ER, Vlasic Kuljanic K, Waldenstrom
AC, Duric VM, Jensen PT, Singer S, Chie W, Nordin A, Radisic Bjelic
V and Wydra D: European Organization for Research and Treatment of
Cancer Quality-of-Life Group: The European Organization for
Research and Treatment of Cancer (EORTC) quality-of-life
questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer.
107:1812–1822. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Smith A, Odronic S, Springer B and
Reynolds J: Solid tumor metastases to the pancreas diagnosed by
fine needle aspiration: A single institution experience and a
review of the literature. J Am Soc Cytopathol. 3:S722014.
View Article : Google Scholar
|
|
30
|
Kucharzewska P, Christianson HC, Welch JE,
Svensson KJ, Fredlund E, Ringnér M, Mörgelin M, Bourseau-Guilmain
E, Bengzon J and Belting M: Exosomes reflect the hypoxic status of
glioma cells and mediate hypoxia-dependent activation of vascular
cells during tumor development. Proc Natl Acad Sci USA.
110:7312–7317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martin R, Srivastava T, Lee J, Raj N, Koth
KA and Whelan HT: Using hyperbaric oxygen for autism treatment: A
review and discussion of literature. Undersea Hyperb Med.
42:353–359. 2015.PubMed/NCBI
|
|
32
|
Higdon B, Youngman L, Regehr M and Chiou
A: Deep frostbite treated with hyperbaric oxygen and thrombolytic
therapies. Wounds. 27:215–223. 2015.PubMed/NCBI
|
|
33
|
Huang ET, Mansouri J, Murad MH, Joseph WS,
Strauss MB, Tettelbach W and Worth ER: UHMS CPG Oversight
Committee: A clinical practice guideline for the use of hyperbaric
oxygen therapy in the treatment of diabetic foot ulcers. Undersea
Hyperb Med. 42:205–247. 2015.PubMed/NCBI
|
|
34
|
Yahara K, Ohguri T, Udono H, Yamamoto J,
Tomura K, Onoda T, Imada H, Nishizawa S and Korogi Y: Radiotherapy
using IMRT boosts after hyperbaric oxygen therapy with chemotherapy
for glioblastoma. J Radiat Res. 58:351–356. 2017.PubMed/NCBI
|
|
35
|
Halle B, Andersen C, Schulz MK and
Kristensen BW: New glioma therapy using specific microRNAs. Ugeskr
Laeger. 174:630–633. 2012.(In Danish). PubMed/NCBI
|
|
36
|
Navarria P, Pessina F, Ascolese A, Cozzi
L, Tomatis S, Riva M, Bello L, Clerici E, Lobefalo F and Scorsetti
M: P13.11 Outcome evaluation of oligometastatic patients with
single, large brain metastases treated with gross total resection
(GTR) followed by hypofractionated stereotactic radiosurgery (HSRS)
on the tumor bed. Neuro Oncol. 18:iv712016. View Article : Google Scholar
|
|
37
|
Kępka L, Tyc-Szczepaniak D, Bujko K,
Olszyna-Serementa M, Michalski W, Sprawka A, Trąbska-Kluch B,
Komosińska K, Wasilewska-Teśluk E and Czeremszyńska B: Stereotactic
radiotherapy of the tumor bed compared to whole brain radiotherapy
after surgery of single brain metastasis: Results from a randomized
trial. Radiother Oncol. 121:217–224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Igaki H, Harada K, Umezawa R, Miyakita Y,
Ohno M, Takahashi M, Sumi M, Inaba K, Murakami N, Ito Y, et al:
Outcomes of surgery followed by local brain radiotherapy compared
with surgery followed by whole brain radiotherapy for single brain
metastasis. Tumori. 103:367–373. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bennett EE, Angelov L, Vogelbaum MA,
Barnett GH, Chao ST, Murphy ES, Yu JS, Suh JH, Jia X, Stevens GHJ,
et al: The prognostic role of tumor volume in the outcome of
patients with single brain metastasis after stereotactic
radiosurgery. World Neurosurg. 104:229–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ogbureke KU, Weinberger PM, Looney SW, Li
L and Fisher LW: Expressions of matrix metalloproteinase-9 (MMP-9),
dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at
histologically negative surgical margins may predict recurrence of
oral squamous cell carcinoma. Oncotarget. 3:286–298. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang W, Lu J, Yang L and Zhang J:
Association of matrix metalloproteinase-9 gene −1562C/T
polymorphism with essential hypertension: A systematic review and
meta-analysis article. Iran J Public Health. 44:1445–1452.
2015.PubMed/NCBI
|
|
42
|
Rittling SR and Singh R: Osteopontin in
immune-mediated diseases. J Dent Res. 94:1638–1645. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu LZ, Liu XL and Xie QZ: Osteopontin
facilitates invasion in human trophoblastic cells via promoting
matrix metalloproteinase-9 in vitro. Int J Clin Exp Pathol.
8:14121–14130. 2015.PubMed/NCBI
|
